Cargando…

Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer

BACKGROUND: Manual quantification of the metabolic tumor volume (MTV) from whole-body (18)F-FDG PET/CT is time consuming and therefore usually not applied in clinical routine. It has been shown that neural networks might assist nuclear medicine physicians in such quantification tasks. However, littl...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Manuel, Kersting, David, Umutlu, Lale, Schäfers, Michael, Rischpler, Christoph, Fendler, Wolfgang P., Buvat, Irène, Herrmann, Ken, Seifert, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426242/
https://www.ncbi.nlm.nih.gov/pubmed/33674891
http://dx.doi.org/10.1007/s00259-021-05270-x
_version_ 1783750001508220928
author Weber, Manuel
Kersting, David
Umutlu, Lale
Schäfers, Michael
Rischpler, Christoph
Fendler, Wolfgang P.
Buvat, Irène
Herrmann, Ken
Seifert, Robert
author_facet Weber, Manuel
Kersting, David
Umutlu, Lale
Schäfers, Michael
Rischpler, Christoph
Fendler, Wolfgang P.
Buvat, Irène
Herrmann, Ken
Seifert, Robert
author_sort Weber, Manuel
collection PubMed
description BACKGROUND: Manual quantification of the metabolic tumor volume (MTV) from whole-body (18)F-FDG PET/CT is time consuming and therefore usually not applied in clinical routine. It has been shown that neural networks might assist nuclear medicine physicians in such quantification tasks. However, little is known if such neural networks have to be designed for a specific type of cancer or whether they can be applied to various cancers. Therefore, the aim of this study was to evaluate the accuracy of a neural network in a cancer that was not used for its training. METHODS: Fifty consecutive breast cancer patients that underwent (18)F-FDG PET/CT were included in this retrospective analysis. The PET-Assisted Reporting System (PARS) prototype that uses a neural network trained on lymphoma and lung cancer (18)F-FDG PET/CT data had to detect pathological foci and determine their anatomical location. Consensus reads of two nuclear medicine physicians together with follow-up data served as diagnostic reference standard; 1072 (18)F-FDG avid foci were manually segmented. The accuracy of the neural network was evaluated with regard to lesion detection, anatomical position determination, and total tumor volume quantification. RESULTS: If PERCIST measurable foci were regarded, the neural network displayed high per patient sensitivity and specificity in detecting suspicious (18)F-FDG foci (92%; CI = 79–97% and 98%; CI = 94–99%). If all FDG-avid foci were regarded, the sensitivity degraded (39%; CI = 30–50%). The localization accuracy was high for body part (98%; CI = 95–99%), region (88%; CI = 84–90%), and subregion (79%; CI = 74–84%). There was a high correlation of AI derived and manually segmented MTV (R(2) = 0.91; p < 0.001). AI-derived whole-body MTV (HR = 1.275; CI = 1.208–1.713; p < 0.001) was a significant prognosticator for overall survival. AI-derived lymph node MTV (HR = 1.190; CI = 1.022–1.384; p = 0.025) and liver MTV (HR = 1.149; CI = 1.001–1.318; p = 0.048) were predictive for overall survival in a multivariate analysis. CONCLUSION: Although trained on lymphoma and lung cancer, PARS showed good accuracy in the detection of PERCIST measurable lesions. Therefore, the neural network seems not prone to the clever Hans effect. However, the network has poor accuracy if all manually segmented lesions were used as reference standard. Both the whole body and organ-wise MTV were significant prognosticators of overall survival in advanced breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05270-x.
format Online
Article
Text
id pubmed-8426242
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-84262422021-09-09 Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer Weber, Manuel Kersting, David Umutlu, Lale Schäfers, Michael Rischpler, Christoph Fendler, Wolfgang P. Buvat, Irène Herrmann, Ken Seifert, Robert Eur J Nucl Med Mol Imaging Original Article BACKGROUND: Manual quantification of the metabolic tumor volume (MTV) from whole-body (18)F-FDG PET/CT is time consuming and therefore usually not applied in clinical routine. It has been shown that neural networks might assist nuclear medicine physicians in such quantification tasks. However, little is known if such neural networks have to be designed for a specific type of cancer or whether they can be applied to various cancers. Therefore, the aim of this study was to evaluate the accuracy of a neural network in a cancer that was not used for its training. METHODS: Fifty consecutive breast cancer patients that underwent (18)F-FDG PET/CT were included in this retrospective analysis. The PET-Assisted Reporting System (PARS) prototype that uses a neural network trained on lymphoma and lung cancer (18)F-FDG PET/CT data had to detect pathological foci and determine their anatomical location. Consensus reads of two nuclear medicine physicians together with follow-up data served as diagnostic reference standard; 1072 (18)F-FDG avid foci were manually segmented. The accuracy of the neural network was evaluated with regard to lesion detection, anatomical position determination, and total tumor volume quantification. RESULTS: If PERCIST measurable foci were regarded, the neural network displayed high per patient sensitivity and specificity in detecting suspicious (18)F-FDG foci (92%; CI = 79–97% and 98%; CI = 94–99%). If all FDG-avid foci were regarded, the sensitivity degraded (39%; CI = 30–50%). The localization accuracy was high for body part (98%; CI = 95–99%), region (88%; CI = 84–90%), and subregion (79%; CI = 74–84%). There was a high correlation of AI derived and manually segmented MTV (R(2) = 0.91; p < 0.001). AI-derived whole-body MTV (HR = 1.275; CI = 1.208–1.713; p < 0.001) was a significant prognosticator for overall survival. AI-derived lymph node MTV (HR = 1.190; CI = 1.022–1.384; p = 0.025) and liver MTV (HR = 1.149; CI = 1.001–1.318; p = 0.048) were predictive for overall survival in a multivariate analysis. CONCLUSION: Although trained on lymphoma and lung cancer, PARS showed good accuracy in the detection of PERCIST measurable lesions. Therefore, the neural network seems not prone to the clever Hans effect. However, the network has poor accuracy if all manually segmented lesions were used as reference standard. Both the whole body and organ-wise MTV were significant prognosticators of overall survival in advanced breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05270-x. Springer Berlin Heidelberg 2021-03-05 2021 /pmc/articles/PMC8426242/ /pubmed/33674891 http://dx.doi.org/10.1007/s00259-021-05270-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Weber, Manuel
Kersting, David
Umutlu, Lale
Schäfers, Michael
Rischpler, Christoph
Fendler, Wolfgang P.
Buvat, Irène
Herrmann, Ken
Seifert, Robert
Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
title Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
title_full Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
title_fullStr Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
title_full_unstemmed Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
title_short Just another “Clever Hans”? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer
title_sort just another “clever hans”? neural networks and fdg pet-ct to predict the outcome of patients with breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426242/
https://www.ncbi.nlm.nih.gov/pubmed/33674891
http://dx.doi.org/10.1007/s00259-021-05270-x
work_keys_str_mv AT webermanuel justanothercleverhansneuralnetworksandfdgpetcttopredicttheoutcomeofpatientswithbreastcancer
AT kerstingdavid justanothercleverhansneuralnetworksandfdgpetcttopredicttheoutcomeofpatientswithbreastcancer
AT umutlulale justanothercleverhansneuralnetworksandfdgpetcttopredicttheoutcomeofpatientswithbreastcancer
AT schafersmichael justanothercleverhansneuralnetworksandfdgpetcttopredicttheoutcomeofpatientswithbreastcancer
AT rischplerchristoph justanothercleverhansneuralnetworksandfdgpetcttopredicttheoutcomeofpatientswithbreastcancer
AT fendlerwolfgangp justanothercleverhansneuralnetworksandfdgpetcttopredicttheoutcomeofpatientswithbreastcancer
AT buvatirene justanothercleverhansneuralnetworksandfdgpetcttopredicttheoutcomeofpatientswithbreastcancer
AT herrmannken justanothercleverhansneuralnetworksandfdgpetcttopredicttheoutcomeofpatientswithbreastcancer
AT seifertrobert justanothercleverhansneuralnetworksandfdgpetcttopredicttheoutcomeofpatientswithbreastcancer